Related Experiment Video

Updated: Aug 16, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Epidermal growth factor receptor as a therapeutic target in lung cancer

Joan H Schiller1

  • 1Comprehensive Cancer Center, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA. jhschill@facstaff.wisc.edu

Seminars in Respiratory and Critical Care Medicine
|August 10, 2005
PubMed

Insights

Research reveals molecular differences between cancer and noncancer cells, focusing on the epidermal growth factor receptor (EGFR). Targeted therapies like EGFR tyrosine kinase inhibitors show promise for treating non-small cell lung cancer (NSCLC).

Area of Science:

  • Molecular oncology
  • Cancer cell biology
  • Drug discovery

Background:

  • Decades of research have elucidated molecular distinctions between cancer and normal cells.
  • Several molecular growth factors and receptors are implicated in tumor development and are differentially expressed in tumor cells.

Purpose of the Study:

  • To characterize the structure and function of the epidermal growth factor receptor (EGFR).
  • To explore EGFR as a target for anticancer therapy due to its role in tumor proliferation, survival, and invasiveness.

Main Methods:

  • Investigating molecular differences between cancer and noncancerous cells.
  • Characterizing the structure and function of EGFR.
  • Evaluating targeted therapies such as small-molecule EGFR tyrosine kinase inhibitors and EGFR monoclonal antibodies.

Main Results:

  • Overexpression of EGFR is observed in various epithelial cell tumors, notably non-small cell lung cancer (NSCLC).
  • EGFR-targeted agents have demonstrated therapeutic activity against NSCLC.

Conclusions:

  • Targeting EGFR represents a novel and promising therapeutic strategy for NSCLC.
  • Ongoing clinical trials are evaluating the efficacy of these targeted agents in NSCLC patients.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...